Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Building a Biotech From Zero (Part 2 of 2): Investor Reality, Liquidity Myths & Founder Dynamics
-
Lu par :
-
De :
À propos de ce contenu audio
In Part 2, Ray and David continue their deep dive into the realities of early-stage biotech growth—moving into warrant coverage, investor upside, dilution, and the often-overlooked truth that early equity can be illiquid for years.
David breaks down liquidation waterfalls, down rounds, fiduciary duties, and what happens when a company approaches insolvency.
They close with a candid look at managing founder relationships, avoiding “dead equity,” and keeping the company aligned when the science, money, and people all collide.
- 01:43 Understanding Conversion Discounts
- 02:07 Negotiation Points and Valuation
- 03:11 Enterprise Value and Share Price
- 04:37 Impact on Founders' Equity
- 08:47 Capital Gains Tax Benefits
- 13:47 Liquidity and Exit Strategies
- 19:07 Investor Motivations and Risks
- 34:20 Board and Management Obligations
- 43:11 Ray's Retreat Overview
Aucun commentaire pour le moment